An experimental cancer vaccine developed by Merck and Moderna has shown promising results in a clinical trial for melanoma patients. The vaccine, tailored to each patient's tumor, reduced the risk of cancer recurrence by 42% within two years compared to those who did not receive it. While the treatment has not yet proven to extend overall survival, the findings mark a significant step forward in the long-sought pursuit of therapeutic cancer vaccines. The vaccine is administered alongside pembrolizumab (Keytruda), an immune checkpoint inhibitor that helps unleash the body’s immune response against cancer cells.
The success hinges on recent advances in genetic sequencing and mRNA technology, both of which were accelerated during the COVID-19 pandemic. By identifying unique proteins—called neoantigens—on tumor cells, scientists can design personalized vaccines that teach the immune system to recognize and attack cancer. The federal government has invested $200 million in a public-private partnership to expand this research, and institutions like Memorial Sloan Kettering have established dedicated centers for cancer vaccine development.
Experts remain cautiously optimistic. While melanoma is particularly responsive to immunotherapy, it remains unclear whether the approach will work as effectively on other cancers, such as pancreatic or brain tumors. Still, researchers believe this is just the beginning. “This is the first step,” said Dr. Robert Vonderheide of the University of Pennsylvania. “Will it work in other tumors? I’m hopeful.”
Source: New York Times Business · Summarized by HeadlinesBriefing